Cannabis & Synthetic Cannabinoids
-
Register
- Non-Member - $39
- Regular Member - $29
- Retired - $29
- Early Career Physician - $29
- Resident - $19
- Student - $19
- Associate - $19
- ASAM Staff - Free!
- International Member - $29
- Emeritus Member - $29
- Provisional Member - $29
- Fellow Member - $29
- Honorary Member - $29
- CRT Member - $29
Cannabis & Synthetic Cannabinoids
Recorded: Thursday, September 29, 2022 - Saturday, October 1, 2022
On-Demand Session
Overview
This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course outlines some of the interesting findings and topics that have emerged in research on cannabis. Topics will include adolescent cannabis use, oral cannabinoid products, treatment of pain with cannabis, and psychiatric outcomes for patients with Cannabis Use Disorder (CUD).
Cannabis is the most used federally illegal drug in the United States. Over the last several years there has been a steady increase in research on cannabis, and This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course outlines some of the interesting findings and topics that have emerged. Topics will include adolescent cannabis use, oral cannabinoid products, treatment of pain with cannabis, and psychiatric outcomes for patients with Cannabis Use Disorder (CUD). Following each presentation, presenters answer audience questions.
This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.
- A Different Perspective on Adolescent Cannabis Use
This presentation reframes the issue of adolescent cannabis use from a risk behavior to a reflection of trauma and adversity. First, the presenter will discuss the epidemiology of adolescent cannabis use, noting that the majority of early initiators and daily users have experienced substantial adversity. Next, she will summarize a mismatch between school-based prevention programs and determinants of use. The central argument is that approaches for preventing adolescent cannabis use should involve ensuring that young people have the resources to thrive. - Using Human Laboratory Methods to Understand the Pharmacokinetics and Pharmacodynamics of Oral Cannabinoid Products
This talk will summarize results from human laboratory studies on cannabis edibles. Topics include differences in the effects of cannabis edibles and other routes of cannabis administration (e.g., smoked vs vaped), product and user factors that influence edible effects, drug-drug interactions between oral THC/CBD and common medications, interactive effects between THC and CBD when orally administered, and measuring impairment from cannabis edibles. Clinical and regulatory implications will be discussed and an overview of clinical laboratory methods will be given. - Cannabis and the Pain Dilemma
A concise review of the research on treating pain using different forms of cannabis, including practical approaches to patients who use a variety of products for this indication. Note that this session does not include an endorsement of any particular cannabis formulations or products for the treatment of pain, but rather discusses the current state of evidence and how it can inform clinical work. Participants will also receive a list of further reading/resources to expand their understanding of the concepts presented. - Psychiatric Outcomes in Individuals with Cannabis Use Disorder
This session will review research on psychiatric outcomes related to cannabis use. The focus of the presentation will be negative affect states (e.g. depression, anxiety, suicidal ideation) associated with regular cannabis use, and changes in symptoms of negative affect associated with cannabis use reduction or abstinence. Clinical implications in the management of cannabis use disorder will be discussed, including off-label medications that have been studied for the treatment of cannabis use disorder and that may impact negative affect states.
These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:
- Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
- Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
- Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine
This conference addresses all 6 ACGME Competencies.
Learning Objectives
At the end of the course, learners should be able to:
- Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
- Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
- Develop practical applications for integrating new and emerging science into practice.
- Identify gaps in the field of addiction medicine that future research can address.
- Create a network of colleagues and resources to support the learner's practice or form future research collaborations.
Registration Rates
| ASAM Learner Type | Rate |
| ASAM Member | $29 |
| Non-Member | $39 |
| Associate Member | $19 |
| Resident Member* | $19 |
| Student Member* | $19 |
*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Membership Question? Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.
Refunds & Cancellations
All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Registration Deadline: 10/1/2025
Instructions
- Click on the Contents tab to begin this activity.
- Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
- Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org
ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
Frank J. Vocci, PhD (Moderator)
President and Senior Research Scientist, Friends Research Institute, Inc.
Following a post-doctoral fellowship in addiction pharmacology at the Medical College of Virginia, Dr. Frank Vocci spent 11 years at the FDA where he reviewed applications for marketing of analgesic medications and also participated in domestic and international drug scheduling issues. In 1989, he joined the Medications Development Program at the National Institute on Drug Abuse and became the Director of the Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMC) in 1997. During his tenure at NIDA, four addiction drug products that were developed or co-developed by his division were approved by the FDA and another was approved following his retirement from NIH in 2010. Following his retirement from NIDA in December 2008 Dr. Vocci became President of Friends Research Institute in January 2009. He has published over 100 articles and book chapters and has participated as a grant reviewer for the Department of Defense, the Veterans Administration, the National Institutes of Health, the Brain Research Foundation, and the Peter Dodge Foundation, He is a Past-President of the College on Problems of Drug Dependence and a co-editor of the Journal of Addiction Medicine.
Does Disclose - 1. Takeda Pharmaceutical Co. - Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received), 2. Nirsum Labs - Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received), 3. Revive Therapeutics - Consultant/Advisory Board,Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received)
Renee Johnson, PhD, MPH
Associate Professor
Johns Hopkins Bloomberg School of Public Health
Renee M. Johnson, PhD, MPH; Vice Chair for Diversity, Equity, and Inclusion & Associate Professor, Johns Hopkins Bloomberg School of Public Health, Dept. of Mental Health.
Dr. Johnson is a graduate of Spelman College (BA) and the University of North Carolina at Chapel Hill Gillings School of Global Public Health (MPH, PhD), and she conducted post-doctoral studies at Harvard TH Chan School of Public Health. She is currently on the faculty at Johns Hopkins Bloomberg School of Public Health and is engaged in training public health students in substance use epidemiology. In addition to teaching courses in the area, she directs a NIDA-funded program for pre- and post-doctoral fellows to develop expertise in substance use epidemiology. Dr. Johnson's research is centered on understanding and addressing emotional and behavioral problems among adolescents and emerging adults, with an emphasis on substance use. She has a particular focus on vulnerable youth, including youth who: are Black, Latinx or in other minoritized race/ethnicity groups; reside in low-income, urban areas; are sexual and/or gender minority; and who have been exposed to trauma, adversity, and violence. She has published more than 100 articles on adolescent health, most addressing substance use and related harms. She studies all of the major drugs of abuse, and has a special interest in cannabis. Dr. Johnson guest edited a special issue of Prevention Science entitled “Adolescent and Emerging Adult Marijuana Use in the Midst of Policy and Social Change.” She is on the editorial boards of JAMA Pediatrics and Drug & Alcohol Dependence, and also serves the Journal of Cannabis Research as Section Editor for epidemiology.
No Relevant Financial Disclosures
Tory Spindle, PhD
Assistant Professor
Johns Hopkins University
Dr. Tory Spindle obtained his PhD in Experimental Health Psychology from Virginia Commonwealth University. Broadly, Dr. Spindle utilizes human laboratory studies to characterize the behavioral pharmacology of cannabis and individual cannabis constituents. His research seeks to understand how factors such as route of administration (oral, vaped, smoked, topical), dose, product formulation/chemical composition profile, and user factors (e.g., puffing topography, sex, tolerance) impacts the pharmacokinetic and pharmacodynamic effects of cannabis. Another emphasis of his work is on characterizing cognitive, psychomotor, and driving impairment associated with cannabis, when used alone and in combination with alcohol. Overall, Dr. Spindle’s work is intended to inform policy decisions involving cannabis such as product standards and accessibility, dosing guidelines, and procedures for detecting cannabis impairment. Because the overarching goal of his research is to inform policies and regulatory actions for cannabis, his work can be best described as “cannabis regulatory science.”
Does Disclose: Canopy Growth Corporation. Serve as a paid consultant
Tauheed Zaman
MD
Tauheed Zaman, MD, is an addiction psychiatrist at the San Francisco VA Health Care System and the University of California at San Francisco. He serves as Medical Director of the VA's Addiction Consult and Opioid Safety Team, and as Associate Director for the UCSF Addicion Psychiatry Fellowship. He was Chair of the California Society of Addiction Medicine (CSAM) 2019 annual conference, and now serves on the organization's board of directors. He completed his addiction fellowship at UCSF, and his adult psychiatry training at Harvard Medical School.
No relevant financial disclosures.
Larissa T. Mooney
MD
Larissa Mooney, MD is a board certified addiction psychiatrist and Associate Clinical Professor of Psychiatry at the University of California, Los Angeles (UCLA). She is the Director of the UCLA Addiction Psychiatry Clinic and Chief of the Greater Los Angeles Veterans Affairs Substance Use Disorders Section, where she supervises psychiatrists in training in the clinical management of addictive and mental health disorders. Dr. Mooney is Past President of the American Academy of Addiction Psychiatry (AAAP), a Distinguished Fellow of the American Psychiatric Association (APA), and a Fellow of the American Association of Addiction Medicine (ASAM). Dr. Mooney has conducted research at UCLA Integrated Substance Abuse Programs on pharmacological and behavioral treatment interventions for addictive disorders. She is one of two PIs for the Greater Southern California Node of the National Institute on Drug Abuse (NIDA) Clinical Trials Network. She has current NIDA funding to study functional outcomes in cannabis users and treatment interventions for opioid use disorder and stimulant use disorder.
No Relevant Financial Disclosures
CME, CE, CEU and Other Credit Types
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
NAADAC, the Association for Addiction Professionals
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1222
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1222
Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.
Maintenance of Certification (MOC) / Continuing Certification Program (CCP)
The ASAM State of the Art Course meets the CME requirements for the following primary boards:
• American Board of Medical Specialties (ABMS)
• American Board of Preventive Medicine (ABPM)
• American Board of Anesthesiology (ABA)
• American Board of Pediatrics (ABP)
• American Board of Internal Medicine (ABIM)
• American Board of Surgery (ABS)
• American Board of Psychiatry and Neurology (ABPN)
• American Board of Addiction Medicine (ABAM)
• Royal College of Physicians and Surgeons of Canada (RCPSC
Disclosure Information
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
Key:
Complete
Next
Failed
Available
Locked